linjc16/ctgov huggingface dataset:
The 3-Dimensional Ultrasound for Fetal Anomaly Scan

Study Overview
=================
Brief Summary
-----------------
The aim of this study is 1) to study the clinical application of 3D/4D ultrasound for fetal scanning during pregnancy; 2) ) to study the clinical application of 3D/4D ultrasound for pelvic scanning; 3) to demonstrate how to optimally display the different organs. 4) to correlate our findings with other diagnostic tools like MRI, CT; 5) to correlate our findings with clinical outcome.

Detailed Description
-----------------
A prospective studies of patients that coming to the ultrasound (US) unit in Sheba Medical Center from November 2007 for diagnostic US examination. Patients will receive information of the study (printed and oral) and will ask to sign informed consent to act as a research subject and permission to use personal heath information for research. Studies is performed using commercially available ultrasound equipment (Voluson 730 Expert, General Electric Healthcare, Kretztechnik, Zipf, Austria) with volumetric abdominal RAB 4-8 MHz and volumetric transvaginal RIC 5-9 MHz transducer probes. During the examination of the patient pictures and 3D/4D volumes will acquired either by static 3D or 4D Volume or STIC (Spacio Temporal Image Corelation), Contrast Imaging in plane C (VCI-C) with and without Doppler (Color, Power and High Definition) and with B-flow. Image quality will be assessed in various modes. For optimizing the image volumes manipulations will be performed by positioning of the

Official Title
-----------------
The 3-Dimensional Ultrasound for Fetal Anomaly Scan.

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant woman who come for fetal anomaly scan. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
to study the clinical application of 3D/4D ultrasound for fetal scanning, to study the clinical application of 3D/4D ultrasound for pelvic scanning;, to demonstrate how to optimally display the different organs., to correlate our findings with other diagnostic tools like MRI, CT;, to correlate our findings with clinical outcome.
Observational Study on the Patients With Pain Medications

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe the use of pain treatments in Taiwan, the demographics, clinical characteristics of patients requiring pain treatments, current treatments, outcomes of treatments and the reasons for changing pain medication during treatment.

Detailed Description
-----------------
This is a Phase IV, multi-center, observational study to describe the use of pain treatments, the demographics, clinical characteristics of patients requiring pain treatments, current treatments, outcomes of treatments and the reasons for changing pain medication during treatment. The study is conducted in an effort to understand the status of pain control in Taiwan. Currently in Taiwan, there is no approved documentation showing the most effective standard medication for treatment of patients in pain. Observational study with no study medication administered.

Official Title
-----------------
Observational Study on the Patients With Pain Medications

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Other: Observational pain control study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients only Patients must have pain, previously treated with and without medication and have a VAS (Visual analogue scale) score recorded at the enrolment time Patient must have a VAS score >4 Exclusion Criteria: Patients who are receiving any investigational drug during the study Patients with known or suspected psychotic disease or mental retardation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 001<br> | Other: Observational pain control study<br>* Observational pain control study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe effective use of pain medications, describe demographics, clinical characteristics of patients requiring pain treatments, current treatments, outcomes of treatments and the reasons for changing pain medication during treatment in Taiwan |  | 60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Relief Rating Scale |  | 60 days | 
| Sleeping quality Assessment |  | 60 days | 
| Global Assessments (Patient/Investigator) |  | 60 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pain, Observational, Taiwan
Community-Acquired Pneumonia (CAP) Surveillance

Study Overview
=================
Brief Summary
-----------------
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.

Official Title
-----------------
Community-Acquired Pneumonia (CAP) Mycoplasma Surveillance

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Other: No Drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chinese adult (male or female) ≥18 years old Outpatients or inpatients who suffer from CAP Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Other: No Drug<br>* It's a surveillance<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In vitro Minimal Inhibitory Concentration Detection |  | Up to 27 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In vitro Gene Mutation Detection |  | Up to 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pneumonia, surveillance
Serum Progesterone on the Day of Embryo Transfer and Pregnancy Rate.

Study Overview
=================
Brief Summary
-----------------
This study aims to analyze whether serum Progsterone levels on the day of Embryo Transfer are related with Ongoing Pregnancy rate in artificial endometrial preparation cycles with intravaginal micronized progesterone.

Official Title
-----------------
Impact of Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Endometrial Preparation Cycles on the Ongoing Pregnancy Rate.

Conditions
-----------------
Ongoing Pregnancy Rate

Intervention / Treatment
-----------------
* Diagnostic Test: Analysis of serum Progesterone in blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Age <50 years old Hormonal Replacement therapy cycle for embryo transfer in any of the following situations: Embryos in fresh cycle with donated oocytes. Subsequent embryo transfers of vitrified embryos in cycles of donated oocytes. Frozen embryo transfers in cycles with autologous oocytes. Endometrial line: >6.5-7mm (with trilaminar aspect) in proliferative phase, before introducing progesterone. Administration of natural micronized progesterone intravaginally (400 mg/12 hours for 5 complete days (10 dosis), before the embryo transfer and maintained until pregnancy week 12. Embryo transfer of blastocyst (day 5-6). Signed Informed Consent Exclusion Criteria Uterine pathology (submucous o intramural fibroids (>4 cm) or which deform the uterine cavity; endometrial polyps or Müllerian anomalies; or adnexal anomalies (communicating hydrosalpinx). Simultaneous participation in another clinical study. Participation in another clinical study before the inclusion in the present study, and which could affect the objectives of the present study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of serum Progesterone levels | Serum progesterone levels | The day of embryo transfer | 
| Ongoing Pregnancies depending on Progesterone levels ranges. | Ultrasound to confirm Ongoing Pregnancy | Week 5-12 after Embryo Transfer |
Observing Pelvic Organ Prolapse Symptoms And Treatment Outcomes

Study Overview
=================
Brief Summary
-----------------
To prospectively observe the outcomes of surgical prolapse treatment in terms of urinary, bowel, and sexual function, quality of life, patient satisfaction, cost, and achieving patient determined treatment goals.

Detailed Description
-----------------
Patients meeting the inclusion/exclusion criteria will be identified by reviewing the hospital's surgical boarding list and contacted by phone to obtain informed consent. Once informed consent is obtained, chart review will be conducted here at William Beaumont Hospital and at the physician's office to collect patient information related to their prolapse condition. Prior to surgery, questionnaires will be mailed and completed by the participant and then again at 6 and 12 months after surgery, and then yearly. Questionnaires will assess urinary, bowel, and sexual function, and patient treatment goals, treatment satisfaction, and general health and wellbeing. Completion of the questionnaires will be voluntary, and participants will be followed in this manner until voluntary withdrawal, exclusionary criteria emerge, or death.

Official Title
-----------------
Observing Pelvic Organ Prolapse Symptoms And Treatment Outcomes

Conditions
-----------------
Genital Prolapse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Pelvic Organ Prolapse Able to provide informed consent Able to complete study assessments, per clinician judgment Exclusion Criteria: Age < 21 years Currently pregnant or < 6 months post-partum

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in urinary, bowel, and sexual function as measured on the PFDI, PFIQ, and PISQ validated questionnaires |  | Ongoing | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prolapse, pelvic organ prolapse
Effects of Alkaline Phosphatase on Renal Function in Septic Patients

Study Overview
=================
Brief Summary
-----------------
Septic shock is the most common cause of death in patients requiring intensive care. The kidney is one of the first organs to fail, stressing the importance to search for clinical interventions that may protect the kidneys during sepsis. Alkaline phosphatase functions as a host defence molecule and is present in many cells and organs (e.g. intestine, placenta, liver, kidney and bone). Alkaline phosphatase has a dual mode of action. First, it binds to and, subsequently, dephosphorylates lipopolysaccharide (LPS). Second, the enzymatic reaction product monophosphoryl-LPS is a non-toxic substance for mammals which acts as a partial antagonist on the LPS receptor complex. In several animal studies, administration of alkaline phosphatase attenuates the inflammatory response and reduces mortality. It is unknown whether these results can be extrapolated to septic patients . We studied the effects of alkaline phosphatse administration on kidney damage and function in patients with severe sepsis or septic shock.

Official Title
-----------------
Effects of Alkaline Phosphatase on Renal Function in Patients With Severe Sepsis or Septic Shock.

Conditions
-----------------
Severe, Septic, Shock

Intervention / Treatment
-----------------
* Drug: bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Proven or suspected Gram-negative bacterial infection Two out of four Systemic Inflammatory Response Syndrome (SIRS) criteria existing for less than 24 h Acute onset of end-organ dysfunction in the preceding 12 h Exclusion Criteria: Prior therapy with alkaline phosphatase Known allergy for cow milk Probable death within 24 h Chronic renal failure requiring hemodialysis or peritoneal dialysis Acute pancreatitis with no established source of infection HIV seropositive Pregnant or lactating Confirmed Gram-positive or fungal sepsis Treatment with immunosuppressants including high doses of glucocorticosteroids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biomarkers of kidney damage |  |  | 
| kidney function |  |  | 
| markers of inflammation |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
alkaline phosphatase, sepsis, kidney function
Predictors of Cord Blood Immunoglobin E (IgE) Levels

Study Overview
=================
Brief Summary
-----------------
Background: Increased total serum IgE levels are a common characteristic of atopic diseases. Increased cord blood IgE levels, in conjunction with a family history of atopy, are associated with the development of allergic diseases in children. However, little is known about predictors of cord blood IgE levels. Objective: The aim of our study was to identify predictors of cord blood IgE levels in an ongoing large birth cohort of infants with or without a family history of atopy. Methods: Blood sampling of mothers was performed just before the delivery of newborns. Cord blood was also collected when the child was born. Maternal and cord blood was measured for IgE levels and cytokines. Questionnaires were administered after birth of the infant.

Conditions
-----------------
Atopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mothers in pregnancy 18 years of age or older, AND Mothers able to speak Chinese. Exclusion Criteria: Infant delivered at less than 36 weeks' gestation, Infant with Apgar score in 5 minutes after birth < 7, Infant with a major congenital anomaly, OR Infant admitted to an intensive care unit.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prenatal factors<br>Prenatal factors to predict cord blood IgE | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cord blood IgE |  | at birth | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cord blood cytokines or other mediators |  | at birth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IgE, cord blood, prenatal, predictor
TRAUMA HELP: Healing and Analgesia With Propranolol

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether propranolol can decrease pain symptoms in a common subset of patients admitted to a trauma center after injury.

Detailed Description
-----------------
The main purpose of this pilot study is to investigate Propranolol's utility in the trauma population. Specifically, to see if it reduces pain scores post-injury.

Official Title
-----------------
Phase IIB Study: TRAUMA HELP: Healing and Analgesia With Propranolol

Conditions
-----------------
Trauma

Intervention / Treatment
-----------------
* Drug: Propranolol
* Drug: Propranolol ER
* Drug: Sugar pills


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least one fracture ages 18-60 yrs pain score >= 4 speak and read English Exclusion Criteria: gunshot, stab wound, or assault paraplegia/quadriplegia pregnancy psychotic, suicidal, or homicidal hepatic, kidney failure clinically unstable or intubated at time of recruitment hyperthyroidism propranolol use within the last 6 months significant bradycardia cancer (except basal cell) peripheral vascular disease heart block > 1 degree breastfeeding congestive heart failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Propranolol<br> | Drug: Propranolol<br>* 40 mg<br>* Other names: Innopran;Drug: Propranolol ER<br>* 120 mg twice per day<br>* Other names: Innopran;|
| Placebo Comparator: Sugar pill<br> | Drug: Sugar pills<br>* sugar pill<br>* Other names: Placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily average pain score (0-10 numeric rating pain score recorded daily from patient) after study drug initiation. |  | Study days 1, 3, 5, 7, 10, 13, 17, and 19 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep quality |  | MOS Sleep Scale | 
| Anxiety symptoms |  | 7 days, 6 weeks, 3 months, 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, trauma, propranolol
Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening

Study Overview
=================
Brief Summary
-----------------
This is a retrospective chart review. We hypothesize that patients who have undergone congenital heart surgery, prior to screening of blood products have a significant risk of hepatitis C infection and all such patients would benefit from screening for hepatitis C.

Detailed Description
-----------------
The Adult Congenital Clinic at Emory Hospital routinely screens all patients who have had congenital heart surgery prior to 1992 for hepatitis C antibodies. It is currently not the practice norm for all congenital heart patients to receive hepatitis screening unless they are at a specialized clinic that has implemented a system. The question of hepatitis C serology is particularly important for this population as many of these patients develop heart failure and may require heart transplantation and immunosuppression. This is a retrospective analysis examining the prevalence of hepatitis C in the Adult Congenital Clinic at The Emory Clinic. The current practice is to screen all adult congenital heart disease patients for hepatitis C. All Emory clinic charts reviewed will be of patients who had congenital heart surgery. Only information on patients who had surgery prior to 1992 will be used for this study. We will review approximately 1000 charts for this study.

Official Title
-----------------
Proposal for Retrospective Review of the Prevalence of Hepatitis C Infection in Adult Patients Who Underwent Congenital Heart Surgery Before Screening

Conditions
-----------------
Congenital Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients seen at Emory Adult Congenital Clinic patients > 18 years of age underwent surgery for congenital heart disease prior to 1992 Exclusion Criteria: history of known hepatitis prior to congenital heart surgery history of intravenous drug abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatic Medicine, Surgery